Holen Sie sich die Stockscreener-App
143.18
1.76%
2.47
Handel nachbörslich:
142.40
-0.78
-0.54%
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neurocrine to present Prader-Willi syndrome research at FPWR event - Investing.com
Neurocrine to present Prader-Willi syndrome research at FPWR event By Investing.com - Investing.com Nigeria
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference - PR Newswire
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
Neurocrine Biosciences selects Ruder Finn as communications AOR - Medical Marketing and Media
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - uk.finance.yahoo.com
Neurocrine Price Target Cut to $214.00/Share From $231.00 by UBS - Moomoo
UBS cuts Neurocrine Biosciences stock price target to $214 on competition - Investing.com
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
EBITDA margin % of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return - Simply Wall Street
Neurocrine Biosciences names Eiry Roberts as chief medical officer - Investing.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - marketscreener.com
Neurocrine names Eiry Roberts chief medical officer - Stock Titan
Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes - marketscreener.com
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - PR Newswire
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - stocktwits.com
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Eastern Progress
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - Eastern Progress
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - webull.com
Neurocrine Biosciences stock draws support from strong Q2 figures - AD HOC NEWS
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story - Yahoo Finance
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost - Kalkine Media
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com Nigeria
Neurocrine Biosciences Inc (NBIX) Shares Fall 4.6% -- What GF Sc - GuruFocus
Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) director logs 14,343-share vesting, 7,839 withheld for taxes - Stock Titan
Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - stocktitan.net
Neurocrine Biosciences (NBIX) grants HR chief 3,587 shares - Stock Titan
PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares - stocktitan.net
CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests - Stock Titan
Is Neurocrine Biosciences (NBIX) Still Undervalued As It Heads Into September Conferences? - Simply Wall Street
Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan
Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says - Yahoo Finance
How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
1.70%
5.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):